Case In Point

IRT Support for a Long-Term, Complex Rare Disease Study

About Client

The sponsor is conducting a global, open-label extension (OLE) study involving children and adolescents with a rare neurological disease. The study enrolls patients rolling over from prior Phase II and III studies and requires long-term, frequent dosing and site or home-based visits per protocol.

Everest has served as the Interactive Response Technology (IRT) provider for this program for over 7 years.

Challenge

The study faced several complex operational and logistical issues, including:

  • Limited drug supply availability and tight expiration timelines
  • Complex shipping logistics across multiple countries and protocols
  • Need for individualized patient scheduling and flexible dosing pathways
  • Requirement to manage weight-based dosing, titration, and tapering
  • Restrictions based on country-specific or protocol-specific treatment pathways
  • Need for full traceability and accountability in drug management and delivery

Solution

Everest IRT implemented a comprehensive, adaptive solution to support the trial’s requirements:

  • Supported weight-based dosing, dose titration into OLE, and tapering at discontinuation
  • Introduced variable dosing and assignment models, including: site-level assignment, site-to-patient shipments, and direct depot-to-patient shipments
  • Designed system enhancements to support partial treatment assignments and time-sensitive resupply triggers
  • Drug receipt, returns, usage, and destruction tracking
  • Integrated Everest IRT with Medidata Rave EDC at specific timepoints to facilitate data synchronization and support timely data entry

Results

  • Enabled the study to continue dosing despite drug supply and expiration constraints
  • Maintained protocol compliance across multiple global sites and varying country-specific restrictions
  • Delivered a flexible, patient-centered dosing and logistics approach that supports ongoing trial execution
  • Ensured full traceability and accountability for drug supply across the lifecycle of treatment
AdobeStock_711762972 1

Everest IRT has successfully managed enrollment and treatment for the OLE study for over 7 years.